Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RB1 del |
| Therapy | REC-617 |
| Indication/Tumor Type | Her2-receptor negative breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RB1 del | Her2-receptor negative breast cancer | predicted - sensitive | REC-617 | Preclinical - Cell culture | Actionable | In a preclinical study, REC-617 (GTAEXS617) induced cell cycle arrest and apoptosis in CDK4/6 inhibitor-resistant, ESR1-positive, ERBB2 (HER2)-negative breast cancer cells with Rb deletion (Cancer Res (2025) 85 (8_Supplement_1): 366). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract 366: CDK7 inhibition as a synthetic lethal strategy in Rb-deficient ER+/HER2- breast cancer and sarcoma cells resistant to CDK4/6 inhibitors | Full reference... |